Proteolix

Proteolix, a biopharmaceutical company founded in 2003, has established itself as a pioneer in the development and commercialization of innovative therapies targeting cancers and immunological conditions. Based in South San Francisco, United States, the company focuses on disrupting protein turnover in cells by inhibiting the proteasome.

Their leading product candidate, carfilzomib (PR-171), is administered intravenously and undergoing multiple clinical trials to test its safety and efficacy across various cancer types. In addition to this, Proteolix is advancing a pipeline of next-generation proteasome inhibitors, including oral and selective immunoproteasome inhibitors, aiming to broaden the therapeutic applications of this novel target class.

Having secured a substantial $79.00M Series C investment on 01 September 2008, the company is backed by stalwart investors such as US Venture Partners, Advanced Technology Ventures, Delphi Ventures, and The Vertical Group, among others. This funding supports their continued research and development efforts, positioning Proteolix for potential breakthroughs in cancer treatment.